The Association of the British Pharmaceutical Industry (ABPI) has responded to the publication of the Government’s Accelerated Access Review (AAR).
First launched by the government in March 2015, the aim of the AAR was to make the UK “the fastest place in the world for the design, development and widespread adoption of medical innovations and stimulate new investment, jobs and economic growth to support the NHS”.
The ABPI believes the Review is a significant first step in addressing poor patient access to new medicines in the UK and reflects the Government’s manifesto commitment to increase the use of innovative new medicines for NHS patients.
Chief Executive of the ABPI, Mike Thompson, said:
“The Accelerated Access Review is an important foundation for building a Life Sciences Industrial Strategy and opens the door to greater collaboration between innovators, patients and the NHS to make the UK a world leader in researching, developing and using new treatments and technologies.
If we work together to deliver the necessary step-change in getting innovative medicines to British patients we then could see growth in research and development, manufacturing and employment in a post Brexit UK. Turning this into reality now relies on a positive government response to the Review, and a clear implementation plan.”
## ENDS ##
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.